Acetylcholine Dysregulation in Parkinson's Disease: Pathophysiology and Therapeutic Targets

Parkinson's disease (PD) involves dopaminergic neuron loss in substantia nigra pars compacta. This disrupts the dopamine-acetylcholine balance in the striatum.

Normal Striatal Balance

• Dopamine (D2 receptors) inhibits indirect pathway → facilitates movement.
• Acetylcholine (from cholinergic interneurons) excites indirect pathway → suppresses movement.
• Balance allows smooth motor control.

In PD

• Dopamine depletion → loss of D2 inhibition → indirect pathway overactivity.
• Relative acetylcholine excess (cholinergic interneurons intact) → further suppresses movement.
• Result: bradykinesia, rigidity, tremor.

Effects of Unopposed Cholinergic Activity

• Tremor: ACh modulates thalamocortical circuits; excess amplifies oscillatory activity.
• Rigidity: Increased striatal output → excessive GPi/SNr inhibition of thalamus.
• Bradykinesia: Impaired movement initiation/scaling.
• Postural instability: Later feature; cholinergic depletion in pedunculopontine nucleus (PPN) contributes.
• Cognitive/psychiatric: Cortical cholinergic loss → dementia, hallucinations.

Therapeutic Implications

• Anticholinergics (trihexyphenidyl, benztropine): Block muscarinic receptors → improve tremor/rigidity. Limited benefit for bradykinesia. Side effects: dry mouth, constipation, urinary retention, confusion, falls. Avoid in elderly/cognitive impairment.
• Cholinesterase inhibitors (rivastigmine, donepezil): Boost ACh for dementia; may worsen motor symptoms slightly.
• Dopaminergic therapy (levodopa, agonists): Restores balance indirectly; mainstay.

Current Understanding

It's not simply "unrestrained ACh" but a dynamic imbalance. Early PD: relative ACh excess in striatum. Late PD: cortical cholinergic depletion coexists. Treatment targets specific circuits and symptoms.